Literature DB >> 30229666

Monocyte and Alveolar Macrophage Skewing Is Associated with the Development of Pulmonary Arterial Hypertension in a Primate Model of HIV Infection.

Finja Schweitzer1, Rebecca Tarantelli1, Emily Rayens1, Heather M Kling2, Joshua T Mattila3, Karen A Norris1.   

Abstract

We investigated the relationship of monocytes, alveolar, and tissue-resident macrophage populations and the development of pulmonary arterial hypertension (PAH) in a nonhuman primate model of HIV infection. A prospective study of simian immunodeficiency virus-associated pulmonary arterial hypertension (SIV-PAH) was done. Rhesus macaques (n = 21) were infected with SIV. Blood, bronchoalveolar lavage fluid (BALF), and lung tissue were analyzed for monocyte and macrophage phenotypes and inflammatory mediators. Serial right heart catheterizations were performed at three time points throughout the study to assess hemodynamic alterations and the development of PAH. All 21 animals showed similar courses of SIV infection with an increasing proinflammatory plasma environment. At 6 months postinfection (mpi), 11 of 21 animals developed SIV-PAH (mPAP ≤25 mmHg; right ventricular systolic pressure [RVSP] ≤36 mmHg). PAH+ animals had an increased frequency of proinflammatory, nonclassical monocytes (CD14dimCD16+) (p = .06) in the peripheral blood and CD14+CCR7-CD163-CD206+ macrophages (p = .04) in BALF compared with PAH- animals at 6 mpi. Increased frequencies of these monocyte and macrophage phenotypes correlated with elevated RVSP (p = .04; p = .03). In addition, PAH+ animals had greater frequencies of tissue resident inflammatory M1-like CD68+STAT1+ (p = .001) and M2a-like CD68+STAT3+ macrophages (p = .003) and a lower frequency of anti-inflammatory M2c-like CD68+STAT6+ macrophages (p = .003) as well as fewer interleukin (IL)-10+ cells (p = .01). The results suggest that HIV-PAH is associated with skewing of monocytes and alveolar macrophages toward a proinflammatory, profibrotic phenotype. Furthermore, PAH+ animals may have diminished capacity to downregulate exaggerated chronic inflammation, as indicated by lower levels of IL-10 in PAH+ animals, contributing to disease progression.

Entities:  

Keywords:  HIV-PAH; alveolar macrophage; monocyte; nonhuman primate

Mesh:

Substances:

Year:  2018        PMID: 30229666      PMCID: PMC6343195          DOI: 10.1089/AID.2018.0132

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  81 in total

1.  Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy.

Authors:  S Eddahibi; M Humbert; S Sediame; C Chouaid; C Partovian; B Maître; E Teiger; D Rideau; G Simonneau; O Sitbon; S Adnot
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

Review 2.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

Review 3.  Monocyte and macrophage plasticity in tissue repair and regeneration.

Authors:  Amitava Das; Mithun Sinha; Soma Datta; Motaz Abas; Scott Chaffee; Chandan K Sen; Sashwati Roy
Journal:  Am J Pathol       Date:  2015-06-26       Impact factor: 4.307

4.  Chemokine RANTES in severe pulmonary arterial hypertension.

Authors:  Peter Dorfmüller; Véronique Zarka; Ingrid Durand-Gasselin; Gianpaola Monti; Karl Balabanian; Gilles Garcia; Frédérique Capron; Aurore Coulomb-Lherminé; Anne Marfaing-Koka; Gérald Simonneau; Dominique Emilie; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2002-02-15       Impact factor: 21.405

Review 5.  Macrophages: master regulators of inflammation and fibrosis.

Authors:  Thomas A Wynn; Luke Barron
Journal:  Semin Liver Dis       Date:  2010-07-21       Impact factor: 6.115

6.  Circulating monocytes from patients with primary pulmonary hypertension are hyporesponsive.

Authors:  Baisakhi Raychaudhuri; Tracey L Bonfield; Anagha Malur; Kathleen Hague; Mani S Kavuru; Alejandro C Arroliga; Mary Jane Thomassen
Journal:  Clin Immunol       Date:  2002-08       Impact factor: 3.969

7.  Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension.

Authors:  Olivier Sanchez; Elisabeth Marcos; Frédéric Perros; Elie Fadel; Ly Tu; Marc Humbert; Philippe Dartevelle; Gérald Simonneau; Serge Adnot; Saadia Eddahibi
Journal:  Am J Respir Crit Care Med       Date:  2007-09-06       Impact factor: 21.405

8.  Activated STAT3 is a mediator and biomarker of VEGF endothelial activation.

Authors:  Shao-Hua Chen; Danielle A Murphy; Wiem Lassoued; Gavin Thurston; Michael D Feldman; William M F Lee
Journal:  Cancer Biol Ther       Date:  2008-12-11       Impact factor: 4.742

9.  Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice.

Authors:  R K Sellon; S Tonkonogy; M Schultz; L A Dieleman; W Grenther; E Balish; D M Rennick; R B Sartor
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

10.  CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection.

Authors:  N Thieblemont; L Weiss; H M Sadeghi; C Estcourt; N Haeffner-Cavaillon
Journal:  Eur J Immunol       Date:  1995-12       Impact factor: 5.532

View more
  8 in total

1.  Exploring New Therapeutic Pathways in Pulmonary Hypertension. Metabolism, Proliferation, and Personalized Medicine.

Authors:  M Patricia George; Mark T Gladwin; Brian B Graham
Journal:  Am J Respir Cell Mol Biol       Date:  2020-09       Impact factor: 6.914

2.  Longitudinal Evaluation of Pulmonary Arterial Hypertension in a Rhesus Macaque (Macaca mulatta) Model of HIV Infection.

Authors:  Rebecca A Tarantelli; Finja Schweitzer; Marc A Simon; Rebecca R Vanderpool; Ian Christman; Emily Rayens; Heather M Kling; ToniAnn Zullo; Jonathan P Carney; Brian J Lopresti; Thomas Bertero; Stephen Y Chan; Karen A Norris
Journal:  Comp Med       Date:  2018-12-12       Impact factor: 0.982

3.  Extracellular Vesicle TGF-β1 Is Linked to Cardiopulmonary Dysfunction in Human Immunodeficiency Virus.

Authors:  Balaji Krishnamachary; Aatish Mahajan; Ashok Kumar; Stuti Agarwal; Aradhana Mohan; Ling Chen; Priscilla Y Hsue; Prabhakar Chalise; Alison Morris; Navneet K Dhillon
Journal:  Am J Respir Cell Mol Biol       Date:  2021-10       Impact factor: 6.914

4.  Donepezil Ameliorates Pulmonary Arterial Hypertension by Inhibiting M2-Macrophage Activation.

Authors:  Haihua Qiu; Yibo Zhang; Zhongyu Li; Ping Jiang; Shuhong Guo; Yi He; Yuan Guo
Journal:  Front Cardiovasc Med       Date:  2021-03-15

5.  Mice with humanized immune system as novel models to study HIV-associated pulmonary hypertension.

Authors:  Valerie J Rodriguez-Irizarry; Alina C Schneider; Daniel Ahle; Justin M Smith; Edu B Suarez-Martinez; Ethan A Salazar; Brianyell McDaniel Mims; Fahmida Rasha; Hanna Moussa; Naima Moustaïd-Moussa; Kevin Pruitt; Marcelo Fonseca; Mauricio Henriquez; Matthias A Clauss; Matthew B Grisham; Sharilyn Almodovar
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

Review 6.  An Outlook on the Etiopathogenesis of Pulmonary Hypertension in HIV.

Authors:  Jaimee J Palakeel; Mazin Ali; Phani Chaduvula; Sanika Chhabra; Smriti Lamsal Lamichhane; Vaiishnavi Ramesh; Collins O Opara; Farhana Yaqoob Khan; Gargi Kabiraj; Humaira Kauser; Jihan A Mostafa
Journal:  Cureus       Date:  2022-07-28

7.  HIV Infection Is Associated with Loss of Anti-Inflammatory Alveolar Macrophages.

Authors:  Charles Preston Neff; Shaikh M Atif; Eric C Logue; Janet Siebert; Carsten Görg; James Lavelle; Suzanne Fiorillo; Homer Twigg; Thomas B Campbell; Andrew P Fontenot; Brent E Palmer
Journal:  J Immunol       Date:  2020-09-14       Impact factor: 5.422

8.  Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH.

Authors:  Whitney Rabacal; Finja Schweitzer; Emily Rayens; Rebecca Tarantelli; Patrick Whang; Viviana Cobos Jimenez; Judy A Outwater; Karen A Norris
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.